Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.15% |
| Dec 31, 2025 | 75.04% |
| Sep 30, 2025 | 15.52% |
| Jun 30, 2025 | -24.24% |
| Mar 31, 2025 | 6.49% |
| Dec 31, 2024 | -18.89% |
| Sep 30, 2024 | 30.50% |
| Jun 30, 2024 | 29.23% |
| Mar 31, 2024 | -17.24% |
| Dec 31, 2023 | 36.41% |
| Sep 30, 2023 | -16.08% |
| Jun 30, 2023 | -2.29% |
| Mar 31, 2023 | 41.39% |
| Dec 31, 2022 | 39.24% |
| Sep 30, 2022 | -18.10% |
| Jun 30, 2022 | 15.88% |
| Mar 31, 2022 | -16.43% |
| Dec 31, 2021 | -40.73% |
| Sep 30, 2021 | -17.62% |
| Jun 30, 2021 | -17.10% |